WilmerHale Advises ImmPACT Bio On $111 Million Series B Financing

WilmerHale Advises ImmPACT Bio On $111 Million Series B Financing

Firm News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
WilmerHale has played a leading role in shaping the rules that govern the financial services industry in the United States.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale represented ImmPACT Bio, a clinical-stage company developing transformative logic-gate based chimeric antigen receptor (CAR) T-cell therapies for treating cancer, in its January 2022 $111 million Series B financing.

The financing included co-leads Foresite Capital and Decheng Capital, in addition to Surveyor Capital (a Citadel company). Other investors include the company’s existing investors OrbiMed, Novartis Venture Fund, RM Global Partners (RMGP) and Bukwang Pharmaceutical. The financing proceeds will be used to advance the company’s pipeline of transformative next-generation CAR T-cell therapies that harness the immune system and address key challenges for current cell therapies in cancer.

The WilmerHale team representing ImmPACT Bio included Eric Hanson, Jason Kropp, Victoria Peluso, Naré Aleksanyan and Shaina Hourizadeh.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel